%0 Journal Article %T Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something? %A Marchetti, Claudia %A Rosati, Andrea %A Scambia, Giovanni %A Fagotti, Anna %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something? %K %X Despite initial maximal surgical effort and successful response to medical treatment, recurrence is a common event in high-grade serous ovarian cancer (HGSOC), with 75% of women experiencing relapse within 2 years from diagnosis (1). At relapse, patients with platinum sensitive recurrent ovarian cancer (PSROC) are frequently retreated with platinum-based doublets (2). Furthermore, maintenance therapy should be offered, either with bevacizumab, or with Parp-inhibitors (PARPi) (3-5), if not previously administrated. %U https://atm.amegroups.org/article/view/33943 %P S372 %@ 2305-5847